INSILICO (03696.HK): ISM9528 Begins First-in-Human Dosing

On 17 November 2026, INSILICO (03696.HK) completed first-in-human dosing of ISM9528, an AI-driven non-opioid pain candidate, four months after nomination.

NewTimeSpace News: On 17 November 2026, InSilico Medicine Cayman TopCo (stock code: 3696) announced on a voluntary basis that it has completed the first-in-human dosing of ISM9528, a potential first-in-class non-opioid pain candidate discovered in Abu Dhabi, just four months after its preclinical candidate (PCC) nomination.

According to the announcement, the exploratory trial evaluates the safety, tolerability, pharmacokinetics and pharmacodynamics of orally administered ISM9528 in healthy adult volunteers. As the study proceeds, the Company may submit additional dossiers to the relevant authorities and expand the trial, subject to regulatory authorisation.

ISM9528 was nominated as a PCC in July 2026 by the Company's Abu Dhabi team, becoming its 31st PCC since 2021 and the second to emerge from its UAE research effort. In preclinical studies, it showed favourable efficacy versus standard of care in validated models of acute postsurgical pain and neuropathic pain, with favourable safety properties and rapid systemic absorption plus excellent blood-brain barrier permeability supporting a favourable DMPK profile.

×
Share to WeChat

Open WeChat, use the "Scan", and share to my Moments.